Lv4
466 积分 2023-02-20 加入
Switching to camizestrant at ESR1 mutation emergence before disease progression during first-line treatment of hormone receptor-positive advanced breast cancer (SERENA-6): extended analysis of a double-blind, placebo-controlled, randomised, phase 3 trial
1个月前
已完结
First-Line Camizestrant for Emerging ESR1 -Mutated Advanced Breast Cancer
1个月前
已完结
Switching to camizestrant at ESR1 mutation emergence before disease progression during first-line treatment of hormone receptor-positive advanced breast cancer (SERENA-6): extended analysis of a double-blind, placebo-controlled, randomised, phase 3 trial
1个月前
已完结
Switching to camizestrant at ESR1 mutation emergence before disease progression during first-line treatment of hormone receptor-positive advanced breast cancer (SERENA-6): extended analysis of a double-blind, placebo-controlled, randomised, phase 3 trial
2个月前
已完结
Epidermal growth factor receptor mutations in breast Cancer: Therapeutic challenges and way forward
3个月前
已完结
Eythrocyte–anti-PD1 conjugates in persons with advanced solid tumors resistant to anti-PD1/PDL1: preclinical characterization and results of a phase 1 trial
7个月前
已完结
The impact of nonsense-mediated mRNA decay on genetic disease, gene editing and cancer immunotherapy
8个月前
已完结
To NMD or Not To NMD: Nonsense-Mediated mRNA Decay in Cancer and Other Genetic Diseases
8个月前
已完结
Discovery of LHQ490 as a highly selective fibroblast growth factor receptor 2 (FGFR2) inhibitor
9个月前
已完结
FGFR3 as a therapeutic target of the small molecule inhibitor PKC412 in hematopoietic malignancies
10个月前
已完结
皖公网安备34019202002308
